Corporations and Associations - Revisions
HB0996, the JT Alvey Phenibut Consumer Protection Act, creates a new subtitle in the Health-General Article regulating products containing phenibut, a beta-phenyl-gamma-aminobutyric acid HCL marketed for human consumption. The bill requires retailers that prepare, distribute, sell, or offer phenibut products to disclose the factual basis for any product representations on the label, and it prohibits sale of phenibut products that do not meet that disclosure requirement or that have not been recognized as a dietary ingredient or approved drug by the U.S. Food and Drug Administration.
The bill also bars the sale of phenibut products that are adulterated or contaminated with dangerous substances, and it requires the product label or package to state the amount of phenibut contained in the product. Retailers may not sell phenibut products to individuals under 21, and the law imposes civil penalties, misdemeanor liability, and potential civil damages for violations. It further restricts advertising and marketing by prohibiting therapeutic claims and youth-oriented marketing tactics, including cartoons, superheroes, video game references, and certain placements near schools or in media/events with substantial under-21 audiences.
In addition to the sales and advertising restrictions, the bill directs the Maryland Department of Health to adopt implementing regulations. It also requires the Department, working with the Maryland Hospital Association, to report to the General Assembly by December 31, 2026, on adverse health events observed after phenibut use. The act takes effect October 1, 2025, and it amends Maryland law by adding a new consumer-protection framework specifically for phenibut products.
The available legislative context shows no recorded committee transcript excerpts or vote details, so there is little direct evidence of debate or opposition in the provided materials. Based on the bill’s structure, the overall sentiment appears protective of public health and consumer safety, with an emphasis on preventing misleading claims, youth access, and contaminated products. Any likely contention would center on the breadth of the restrictions, the age-21 sales limit, and the advertising limitations imposed on retailers and product sellers.
HB0996 adds a new regulatory scheme to Maryland’s Health-General Article governing phenibut products. It imposes labeling, disclosure, product-quality, age-restriction, and advertising rules on retailers, manufacturers, wholesalers, and other sellers, and it authorizes civil penalties, misdemeanor enforcement, and civil damages for violations. The bill also requires the Maryland Department of Health to promulgate regulations and to report on adverse health events associated with phenibut use, thereby creating both immediate compliance obligations for sellers and a new state monitoring/reporting function.
The bill’s apparent purpose is consumer and public health protection, and the statutory design reflects a precautionary approach toward phenibut products. Because no committee testimony or vote record is provided, there is no documented split in the materials, but the measure reads as broadly supportive of tighter controls on a substance viewed as potentially risky. The absence of recorded opposition in the supplied context suggests the bill moved without visible controversy in the available record, though the restrictions themselves are substantial.
The main points of contention likely involve whether phenibut should be regulated as tightly as the bill provides, especially given the prohibition on sales to anyone under 21, the ban on therapeutic advertising, and the limits on youth-oriented marketing and placement. Retailers and product sellers may view the labeling, testing, and liability provisions as burdensome, while public health advocates would likely support them as necessary to prevent misleading claims, adulterated products, and adverse health events. The bill also raises potential debate over the FDA-recognition standard and whether phenibut products should be treated as lawful consumer goods at all.